Zentalis Pharmaceuticals (ZNTL) Net Equity Issued and Repurchased (2019 - 2022)

Zentalis Pharmaceuticals' Net Equity Issued and Repurchased history runs 4 years deep, the most recent figure standing at $48.6 million for Q4 2022.

• On a quarterly basis, Net Equity Issued and Repurchased rose 398.72% year-over-year to $48.6 million in Q4 2022; TTM through Sep 2024 was $48.6 million, a 79.12% decrease from a year earlier, with the FY2025 full-year figure at $5.4 million, changed N/A from the prior year.
• Net Equity Issued and Repurchased retreated to $48.6 million in Q4 2022 per ZNTL's latest filing, from $184.3 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $184.3 million in Q2 2022 and bottomed at -$141.7 million in Q4 2020.
• The 4-year median for Net Equity Issued and Repurchased is $65.3 million (2019), against an average of $62.6 million.
• Across the five-year window, Net Equity Issued and Repurchased rose 14.51% in 2021 and soared 398.72% in 2022, its largest moves.
• Year by year, Net Equity Issued and Repurchased stood at $81.9 million in 2019, then sank by 272.98% to -$141.7 million in 2020, then soared by 106.88% to $9.8 million in 2021, then surged by 398.72% to $48.6 million in 2022.
• Per Business Quant, the three latest ZNTL Net Equity Issued and Repurchased figures stand at $48.6 million (Q4 2022), $184.3 million (Q2 2022), and $9.8 million (Q4 2021).